Poly Medicure Q2 FY27 Revenue Jumps 30.8% YoY to ₹580.5 Crore; Margins Improve
Poly Medicure reported a 30.8% YoY consolidated revenue growth to ₹580.5 crore for Q2 FY27. Standalone revenue grew 17.2% to ₹488.3 crore. Consolidated EBITDA margin was 24.0%, and standalone margin reached 27.4%. Consolidated PAT was ₹95.1 crore for the quarter. The company also noted strong international growth and ongoing operational updates.
Significant revenue growth and margin improvement are material financial events that are likely to have a high impact on the company's stock performance and investor perception.
The company reported strong year-on-year revenue growth for both consolidated and standalone results, alongside improved EBITDA margins, indicating positive financial performance.
Poly Medicure Limited announced its unaudited financial results for the second quarter and half-year ended September 30, 2026. The company reported a consolidated revenue from operations of ₹580.5 crore for Q2 FY27, marking a significant year-on-year growth of 30.8%. For the half-year ended September 30, 2027 (H1 FY27), consolidated revenue stood at ₹1,105.9 crore, a 30.6% increase over the same period last year.
Standalone revenue for Q2 FY27 grew by 17.2% YoY to ₹488.3 crore, while H1 FY27 standalone revenue increased by 14.8% YoY to ₹919.4 crore. The company's international business demonstrated robust performance, with consolidated international revenue growing by 35.0% YoY in Q2 FY27 and 13.6% organically. Europe, in particular, showed strong organic growth of 39.6% YoY in Q2 FY27.
Consolidated Operating EBITDA margin for Q2 FY27 was reported at 24.0%, within the guided range of 23-25%. The standalone Operating EBITDA margin stood at 27.4% for Q2 FY27, exceeding the guided range of 25%-27%. Net profit after tax (PAT) for Q2 FY27 was ₹95.1 crore, a 3.6% increase YoY on a consolidated basis. For H1 FY27, consolidated PAT was ₹180.4 crore, a 2.4% decrease YoY.
The company also highlighted key operational updates, including the ongoing operationalization of Medyneo in Brazil and the establishment of a direct UK presence. Product launches and R&D efforts continue, with 12 new products launched in FY27 and a strong R&D team of over 90 professionals. Poly Medicure maintains adequate liquidity, with cash and cash equivalents totaling ₹839.1 crore as of September 30, 2026.
What to do with a filing like this
Poly Medicure Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Poly Medicure Limited. Read the original for the full detail.